Finnhub•2026-04-21
Kyverna Therapeutics, Inc. Presents Registrational Trial Primary Analysis for Miv-Cel in Stiff Person SyndromeKYTX — Kyverna Therapeutics Inc
NASDAQ · Biotechnology · Biotechnology
$9.71-10.26%Market cap536.10M
- Latest Close
- $9.71
- 30-Day Move
- -10.3%
- Market Cap
- $536M
- Shares Outstanding
- 57,130,000
- P/B Ratio
- 2.31
- ROE
- -47.6%
Analyst consensus: Buy · 12 analysts
NASDAQ:KYTXBiotechnology / BiotechnologyDelayed public snapshot
Kyverna Therapeutics Inc
A read-only Alphactor snapshot forKyverna Therapeutics Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$9.71
30-Day Move
-10.3%
Market Cap
$536M
Shares Outstanding
57,130,000
P/B Ratio
2.31
ROE
-47.6%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$9.71
-10.3%last 90 delayed daily bars
Market cap$536M
90D High
$13.67
90D Low
$6.58
Avg Volume
1,266,438
What stands out
Net margin is -411.3%, useful for comparing KYTX against peers in Biotechnology.
KYTX is down 10.3% over the last 30 trading days shown on this page.
Latest operating income is $-39M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Dark Pool Short %
39.3%
Fundamentals snapshot
Latest Close
$9.71
30-Day Move
-10.3%
Market Cap
$536M
Shares Outstanding
57,130,000
P/B Ratio
2.31
ROE
-47.6%
ROA
-41.7%
Operating Margin
-418.3%
Net Margin
-411.3%
Debt / Equity
0.11
Current Ratio
7.75
Latest Revenue
$0
Financial statement snapshot
Revenue
$0
Gross Profit
--
Operating Income
$-39M
Net Income
$-38M
Gross Margin
--
Net Margin
-41129.0%
Current Ratio
7.75
Debt / Equity
0.11
Quality snapshot
Altman Z
2.30
Grey
Piotroski
1
Weak (0-3)
Cash Conversion
0.95x
Rule of 40
--
Insufficient data
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $7M | $-29M | $-29M | $-37M |
| 2023-12-31 | $0 | $-62M | $-60M | $-53M |
| 2024-12-31 | $0 | $-143M | $-127M | $-116M |
| 2025-12-31 | $0 | $-170M | $-161M | $-155M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Finnhub•2026-04-21
Kyverna Therapeutics announces positive primary analysis results from KYSA-8 trial of Miv-Cel in SPSFinnhub•2026-04-21
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual MeetingSeekingAlpha•2026-04-21
Kyverna Therapeutics Positive Phase 2 Readout: Deep Responses, But Very Small SampleBenzinga•2026-04-20
Kyverna Therapeutics shares are trading higher after the company announced longer-term follow-up data from Phase 2 portion of its registrational KYSA-6 trial of miv-cel in patients with generalized myasthenia gravis.After signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$2M
Sell Value
$292,775.6
Buys
2
Sells
1
Buy Value
$2M
Sell Value
$292,775.6
Buy/Sell Ratio
2.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-13 | GEHCHAN NAJI | A | 105,000 | $0.00 |
| 2026-03-13 | GEHCHAN NAJI | A | 18,000 | $0.00 |
| 2026-03-13 | Biddle Warner Weston | A | 350,000 | $0.00 |
| 2026-03-13 | Biddle Warner Weston | A | 58,000 | $0.00 |
| 2026-03-13 | GRASSO MARC | A | 65,000 | $0.00 |
| 2026-03-13 | GRASSO MARC | A | 10,000 | $0.00 |
| 2026-02-24 | Emany Sravan Kumar | A | 42,945 | $0.00 |
| 2026-02-24 | Emany Sravan Kumar | A | 11,006 | $0.00 |
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1,347,397 | 0.02% | 2025-12-31 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,320,654 | 0.02% | 2025-12-31 |
| iShares Trust-iShares Biotechnology ETF | 262,747 | 0.00% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 235,746 | 0.00% | 2025-12-31 |
| Simplify Exchange Traded Funds-Simplify Propel Opportunities ETF | 192,339 | 0.00% | 2025-12-31 |
| Bridgeway Funds, Inc.-Ultra-Small Company Fund | 112,000 | 0.00% | 2025-12-31 |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 117,968 | 0.00% | 2026-02-28 |
| SCHWAB STRATEGIC TRUST-Schwab U.S. Small-Cap ETF | 109,746 | 0.00% | 2025-11-30 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
BlackRock
Filed 2024-05-10
$19M
--
Vanguard Group
Filed 2026-01-29
$17M
+34.7%
D.E. Shaw
Filed 2026-02-17
$5M
--
Citadel Advisors
Filed 2026-02-17
$3M
--
Geode Capital Management
Filed 2026-02-09
$3M
-4.3%
Renaissance Technologies
Filed 2026-02-12
$2M
+8.1%
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
4.25
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
12
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.